Effect of tofacitinib in the treatment of patients with vitiligo

Evaluation of the effect of tofacitinib ointment in comparison with placebo in the treatment of patients with vitiligo undergoing phototherapy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150825023753N27

Enrollment

Registered

2025-04-20

Start date

2025-05-21

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo. Vitiligo

Interventions

Intervention 1: Intervention group: receiving daily tofacitinib ointment for three month. Intervention 2: Control group: receiving placebo daily for three month.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over ?? years Presence of depigmented lesions in the upper, lower limbs, face or trunk that are similar in size and color Not using any topical drugs in the last one month Stable or progressive course of the disease Involvement of at least ??% of the body surface Consent to participate in this study

Exclusion criteria

Exclusion criteria: Any history of skin cancer or immunodeficiency, Unwillingness to participate in the study The impossibility of follow-up and refer for follow-up

Design outcomes

Primary

Measure	Time frame
Vitiligo. Timepoint: 0,45,90 days later. Method of measurement: Physical exam.	—

Secondary

Measure	Time frame
Vitiligo Area Scoring Index. Timepoint: 0,45,90 days later. Method of measurement: The information form for the Vitiligo Area Scoring Index (VASI).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Hekmat

Shiraz University of Medical Sciences

m.hekmat1997@yahoo.com+98 71 3235 1099

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026